23 Nov 2021 Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease Member news
15 Nov 2021 OXURION NV - First patient dosed in Part B of Phase 2 KALAHARI study evaluating multiple administrations of THR-149 versus aflibercept for treatment of Diabetic Macular Edema (DME) Member news
08 Nov 2021 reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program Member news
13 Oct 2021 Oxurion NV announces first patient dosed in its Phase 2 Study evaluating THR-687 for the treatment of Diabetic Macular Edema (DME) Member news
12 Oct 2021 X-Pure®–by-design : Antleron-Rousselot® collaborative-development partnership Member news
06 Oct 2021 Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer Member news
04 Oct 2021 Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease Member news
04 Oct 2021 Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON) Member news
30 Sep 2021 OXURION announces positive results from Part A of Phase 2 Study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
